ASCO daily highlights: Sunday 2nd June
Our team on the ground share 5 key highlights from day 3 at ASCO:
- ADC target expression matters but it is not always clinically relevant: selecting patients based on target expression is critical for Teliso-V in NSQ EGFR wtNSCLC, but not strictly necessary for Sac-TMT in TNBC. Evaluating the expression levels of ADC targets is challenging due to analytical and interpretative issues associated with IHC and the temporal and spatial heterogeneity of tumors. Improvements are urgently needed to fully realize the potential of target expression evaluation for the rapidly expanding range of ADC options.
- Tissue-based and "liquid biopsy" prognostic molecular biomarkers have been identified through independent studies. However, it is crucial to conduct larger clinical trials to confirm the clinical utility of these emerging prognostic biomarkers and incorporate them into clinical practice, thereby facilitating risk-stratified therapy decisions and biomarker-driven clinical trials.
- Osimertinib will become the new standard of care for patients with unresectable stage III EGFRm NSCLC who have not progressed after definitive chemoradiotherapy. Ensuring the practice of EGFR mutation testing in stage III disease is critical to identify patients who might be eligible for or benefit from Osimertinib treatment.
- Consolidation durvalumab will become the new standard of care for patients with LS-SCLC who have not progressed after cCRT. The next step is to implement a personalized, biomarker-driven approach utilizing genomic patient stratification, which can further ensure better results in PFS for patients with SCLC.
- Although biomarker expression is common in gastrointestinal and hepatobiliary tumors, accessing molecular profiling in the community setting has proven to be challenging. Strategic biomarker testing, including ensuring the accessibility of both immunohistochemistry and NGS in standard of care treatment paradigms, is crucial to optimizing the selection of targeted therapies for patients with upper gastrointestinal and hepatobiliary cancers.
Stay tuned to our for more daily highlights at ASCO!
Schedule a meeting with our team at ASCO using the link below:
https://go.diaceutics.com/ASCO2024
References:
Abstract 103 “Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.”; 104 “Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study”.
Abstract 11509 “Molecular characterization of patients with localized Ewing sarcoma targeting discrete prognostic groups: A report from the Children’s Oncology Group”; 11510 “Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study”, 11511 “Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes”.
Abstract LBA4 “Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.”
Resource: abstract LBA5 “ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).”
Resource: ASCO daily news Jun.2, 2024
